通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600867 通化东宝

等待开盘 07-29 09:30:00

{"stockData":{"symbol":"600867","market":"SH","secType":"STK","nameCN":"通化东宝","latestPrice":8.25,"timestamp":1785288403000,"preClose":8.25,"halted":0,"volume":202300,"delay":0,"changeRate":0,"floatShares":1959000000,"shares":1959000000,"eps":0.6315,"marketStatus":"等待开盘","change":0,"latestTime":"07-29 09:30:00","open":8.25,"high":8.25,"low":8.25,"amount":1669000,"amplitude":0,"askPrice":8.25,"askSize":63,"bidPrice":8.24,"bidSize":88,"shortable":0,"etf":0,"ttmEps":0.6315,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785288600000},"marketStatusCode":7,"adr":0,"adjPreClose":8.25,"symbolType":"stock","openAndCloseTimeList":[[1785288600000,1785295800000],[1785301200000,1785308400000]],"highLimit":9.08,"lowLimit":7.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1958542829,"isCdr":false,"pbRate":2.23,"roa":"--","peRate":13.064133,"roe":"1.77%","epsLYR":0.62,"committee":-0.433013,"marketValue":16158000000,"turnoverRate":0.0001,"status":2,"floatMarketCap":16158000000},"requestUrl":"/m/hq/s/600867/tweets","defaultTab":"tweets","newsList":[{"id":"2654888730","title":"通化东宝（600867）披露控股股东股份解押及再质押公告，7月28日股价上涨2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654888730","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654888730?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:17","pubTimestamp":1785248236,"startTime":"0","endTime":"0","summary":"近日，通化东宝药业股份有限公司发布《关于控股股东股份解押及再质押公告》。公告显示，公司控股股东东宝集团于2026年7月27日解除质押给中国建设银行股份有限公司通化分行的33,000,000股股份，并同日将相同数量股份重新质押给该行，用于偿还债务。本次解押及再质押后，东宝集团累计质押股份581,939,472股，占其所持公司股份的93.94%，占公司总股本的29.71%。公告披露了东宝集团财务状况、偿债能力及质押风险应对措施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600867","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654168600","title":"通化东宝最新公告：门冬胰岛素注射液获美国FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654168600","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654168600?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:24","pubTimestamp":1785144259,"startTime":"0","endTime":"0","summary":"通化东宝(600867.SH)公告称，公司与健友股份合作开发的门冬胰岛素注射液正式获得美国食品药品监督管理局(FDA)上市批准，用于改善成人及儿科糖尿病患者的血糖控制。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700022317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","600867","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654183470","title":"通化东宝(600867.SH)拟认购特宝生物可转债不超1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654183470","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654183470?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:01","pubTimestamp":1785139282,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 通化东宝(600867.SH)发布公告，公司参股公司厦门特宝生物工程股份有限公司(证券简称：特宝生物，证券代码：688278)向不特定对象发行可转换公司债券，募集资金总额不超过人民币15.33亿元。公司计划行使优先配售权参与认购特宝生物可转债。本次计划参与认购特宝生物可转债的投资本金不超过1.62亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SABA","600867","BK0188","BK0239","BK0196","688278","FCEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650186077","title":"健友股份：与通化东宝战略合作核心聚焦于美国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2650186077","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650186077?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:33","pubTimestamp":1783676003,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份07月10日在投资者关系平台上答复投资者关心的问题。年报显示，门冬胰岛素正在向欧洲和美国获批中，跟通化东宝的合作未来也包含欧洲市场吗？目前公司与通化东宝的战略合作核心聚焦于美国市场。公司已获得包括门冬胰岛素等相关产品在美国的独家商业化权益，合作协议范围尚未包含欧洲市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","BK0196","BK0188","600867","603707","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324496","title":"6月29日通化东宝涨9.96%，南华丰汇混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324496?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:30","pubTimestamp":1782721851,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日通化东宝涨9.96%，收盘报8.17元，换手率2.97%，成交量58.21万手，成交额4.58亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为南华基金的南华丰汇混合A。南华丰汇混合A目前规模为9.67亿元，最新净值1.864，较上一交易日下跌2.6%，近一年上涨20.91%。南华丰汇混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0239","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324457","title":"通化东宝涨9.96%，交银国际证券一个月前给出“买入”评级，目标价11.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324457?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:30","pubTimestamp":1782721840,"startTime":"0","endTime":"0","summary":"今日通化东宝（600867）涨9.96%，收盘报8.17元。2026年5月12日，交银国际证券研究员丁政宁,诸葛乐懿发布了对通化东宝的研报《三代胰岛素驱动业绩强势复苏，糖尿病产品矩阵快速丰富，维持买入》，该研报对通化东宝给出“买入”评级，认为其目标价为11.2元，现价距离目标价尚有37.09%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为49.76%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的甘坛焕。通化东宝（600867）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647323549","title":"异动快报：通化东宝（600867）6月29日13点21分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2647323549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647323549?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:31","pubTimestamp":1782711063,"startTime":"0","endTime":"0","summary":"证券之星6月29日盘中消息，13点21分通化东宝（600867）触及涨停板。其所属行业生物制品目前上涨。领涨股为三生国健。该股为减肥药，创新药，医药概念热股，当日减肥药概念上涨7.01%，创新药概念上涨6.89%，医药概念上涨4.94%。6月26日的资金流向数据方面，主力资金净流出2582.36万元，占总成交额14.01%，游资资金净流入112.07万元，占总成交额0.61%，散户资金净流入2470.28万元，占总成交额13.4%。近5日资金流向一览见下表：通化东宝主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900016389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645812398","title":"6月23日通化东宝涨6.06%，南华丰汇混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645812398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645812398?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:45","pubTimestamp":1782204347,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日通化东宝涨6.06%，收盘报7.87元，换手率3.21%，成交量62.91万手，成交额4.95亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为南华基金的南华丰汇混合A。南华丰汇混合A目前规模为9.67亿元，最新净值1.9502，较上一交易日上涨1.08%，近一年上涨31.19%。南华丰汇混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600867","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645588124","title":"通化东宝涨6.06%，交银国际证券一个月前给出“买入”评级，目标价11.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645588124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645588124?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:45","pubTimestamp":1782204336,"startTime":"0","endTime":"0","summary":"今日通化东宝（600867）涨6.06%，收盘报7.87元。2026年5月12日，交银国际证券研究员丁政宁,诸葛乐懿发布了对通化东宝的研报《三代胰岛素驱动业绩强势复苏，糖尿病产品矩阵快速丰富，维持买入》，该研报对通化东宝给出“买入”评级，认为其目标价为11.2元，现价距离目标价尚有42.31%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为49.76%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的甘坛焕。通化东宝（600867）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023894","title":"通化东宝：公司基本面持续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023894?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:27","pubTimestamp":1782120432,"startTime":"0","endTime":"0","summary":"公司严格按照法定要求履行信息披露义务，不存在任何应披露而未披露的重大利空事项。尽管公司近期股价出现波动，但公司基本面持续向好。公司2025年实现营业收入29.47亿元，同比增长46.66%，归母净利润及扣非净利润均实现扭亏为盈；2026年一季度延续增长势头，营收同比增长14.76%，归母净利润同比增长16.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023851","title":"通化东宝：公司生产经营及财务状况正常，不存在任何退市风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023851?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:27","pubTimestamp":1782120431,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝06月22日在投资者关系平台上答复投资者关心的问题。公司股价持续下跌通化东宝回复：感谢您对公司的关注。公司生产经营及财务状况正常，不存在任何退市风险。二级市场的股价受宏观环境、国家政策、市场情绪等多方面因素的综合影响。尽管公司2024年受到集采等短期或一次性因素影响，业绩短暂承压，但2025年营收实现同比增长46.66%，归母净利润及扣非净利润均实现扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600867","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023817","title":"通化东宝：2025年度现金分红5.87亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023817","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023817?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:27","pubTimestamp":1782120427,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：问通化东宝管理者，通化东宝号称胰岛素龙头企业，中国有1亿多糖尿病人，2025年利润12亿，你们的股票是大盘涨你也跌，大盘跌你也跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","600867","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023850","title":"通化东宝：2025年公司生物制品制剂总销量超9,000万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023850?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:27","pubTimestamp":1782120425,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝(600867)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！根据吉林日报报道，公司在春节期间设备依旧有在运作，同时节后也是满产，满负荷运行，国内国外订单稳步增长且已经排满了，生产计划已经排到今年年底了，请问情况是否属实？通化东宝回复：感谢您对公司的关注。2025年公司生物制品制剂总销量超9,000万支，同比增长逾56%，国际业务收入突破2亿元，同比大幅增长97.16%。2026年一季度公司生产经营保持良好态势。具体信息敬请关注公司发布的定期报告或相关公告。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0196","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645102389","title":"通化东宝：利拉鲁肽2025年销售80余万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2645102389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645102389?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:24","pubTimestamp":1782120285,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝(600867)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的李董：你好！请问公司2025年度利拉鲁肽国内销售了多少支？及公司痛风双靶点新药THDBH151预计何时进入三期临床。通化东宝回复：感谢您对公司的关注。利拉鲁肽2025年销售80余万支。XO/URAT1双靶点抑制剂（THDBH151片）IIa期临床试验已达到主要终点目标。后续研发进展公司将按照相关规定和要求进行披露，敬请关注公司发布的定期报告或相关公告。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600867","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023855","title":"通化东宝：安睿特重组人白蛋白NDA的获批时间预期及其IPO具体进展，属于东宝集团层面的事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023855","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023855?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:24","pubTimestamp":1782120268,"startTime":"0","endTime":"0","summary":"东宝集团质押比例94.66%，未来半年内到期融资余额约3.95亿元；安睿特重组人白蛋白NDA于2026年3月25日获受理。通化安睿特生物制药股份有限公司系控股股东东宝集团旗下资产，上市公司层面目前未持有安睿特股份。因此，安睿特重组人白蛋白NDA的获批时间预期及其IPO具体进展，属于东宝集团层面的事项，上市公司不便代为作出披露或预测。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600867","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645238950","title":"通化东宝：门冬胰岛素美国BLA已获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645238950","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645238950?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:24","pubTimestamp":1782120267,"startTime":"0","endTime":"0","summary":"2025年海外收入突破2亿元，门冬胰岛素欧美上市\"最快年内获批\"。2025年度分红率高达80.52%，管理层指引2026年收入增长10%以上。关于门冬胰岛素欧美注册进展，公司门冬胰岛素美国BLA已获FDA受理，欧盟MAA已获EMA受理，审评工作正稳步推进，公司积极配合监管机构开展相关工作。相关安排将按照有关规定及时进行信息披露，敬请关注公司发布的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","600867","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645238970","title":"通化东宝：注射用 THDBH120 减重适应症 II 期临床试验已完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2645238970","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645238970?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:24","pubTimestamp":1782120261,"startTime":"0","endTime":"0","summary":"证券之星消息，通化东宝06月22日在投资者关系平台上答复投资者关心的问题。THDBH120减重II期临床已于2025年1月首例给药，员工持股计划设定2027年扣非净利润9亿元。请问：THDBH120减重II期数据何时读出？注射用 THDBH120 减重适应症 II 期临床试验已完成全部受试者入组。后续研发进展及临床试验数据公司将按照相关规定和要求进行披露，敬请关注公司发布的定期报告或相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","600867","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645023892","title":"通化东宝：司美格鲁肽注射液已完成III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2645023892","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645023892?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:24","pubTimestamp":1782120260,"startTime":"0","endTime":"0","summary":"九源基因2025年年报披露其司美审评\"暂停\"；翰宇药业走化药2.2类豁免数据保护，5月8日NDA获受理，降糖 减重双适应症均完成III期。公司司美格鲁肽注射液已完成III期临床试验，已于2026年2月提交Pre-NDA申请，NDA申报工作正全面推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645028025","title":"通化东宝：关于注射笔赠送政策的具体情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2645028025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645028025?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:24","pubTimestamp":1782120258,"startTime":"0","endTime":"0","summary":"关于注射笔赠送政策的具体情况，由于各地区、各销售渠道及不同时期的促销政策可能存在差异，建议您通过以下方式获取最准确与及时的信息：拨打公司售后服务免费咨询热线8008465777/4008465777，我们将竭诚为您提供帮助；咨询购药渠道，向您家人日常购买甘舒霖的医院药房或零售药店询问；关注公司线上旗舰店。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200025233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0239","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644741633","title":"通化东宝：公司聘任李佳鸿先生为总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2644741633","media":"证券日报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644741633?lang=zh_cn&edition=full","pubTime":"2026-06-17 21:08","pubTimestamp":1781701680,"startTime":"0","endTime":"0","summary":"证券日报网讯6月17日，通化东宝发布公告称，公司聘任李佳鸿先生为总裁。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-17/doc-inicttai6897580.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-17/doc-inicttai6897580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600867","BK0239","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785288423579,"stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":0.1104},{"period":"3month","weight":-0.1046},{"period":"6month","weight":-0.0295},{"period":"1year","weight":0.04},{"period":"ytd","weight":0.0476}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0716},{"period":"6month","weight":-0.0829},{"period":"1year","weight":0.0599},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化东宝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"103178人(较上一季度增加20.31%)","perCapita":"18982股","listingDate":"1994-08-24","address":"吉林省通化市通化县东宝新村","registeredCapital":"195854万元","survey":"　　通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂、甘精胰岛素原料药、甘精胰岛素注射液、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素、利拉鲁肽注射液、恩格列净片、镇脑宁胶囊、糖尿病相关的医疗器械。公司拥有国家级企业技术中心、国家GMP和欧盟GMP认证的生产车间。被国家认定为高新技术企业、国家技术创新示范企业、ISO14001环境体系认证企业。","listedPrice":6.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化东宝,600867,通化东宝股票,通化东宝股票老虎,通化东宝股票老虎国际,通化东宝行情,通化东宝股票行情,通化东宝股价,通化东宝股市,通化东宝股票价格,通化东宝股票交易,通化东宝股票购买,通化东宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}